<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03959228</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL18_0957</org_study_id>
    <nct_id>NCT03959228</nct_id>
  </id_info>
  <brief_title>Impact of Low Protein Diet Supplemented With Ketoanalogues Supplementation on Uremic Toxins Production</brief_title>
  <acronym>KETO-GUT</acronym>
  <official_title>Impact of Low Protein Diet Supplemented With Ketoanalogues on Uremic Toxins Production and Glucose Metabolism in Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic kidney disease (CKD) is associated with accumulation of uremic toxins like p-cresyl
      sulfate and indoxyl sulfate that are associated of cardiovascular complication and
      perturbation of glucose metabolism. These toxins are produced by fermentation of protein by
      intestinal microbiota but the role of low protein diet and ketoanalogue supplementation on
      uremic toxins production and microbiota composition are unknown. Low protein diet
      supplemented with ketoanalogues is recommended inCKD patients to prevent progression of renal
      disease. The aim of this study is to determine the impact of uremic toxins concentration,
      microbiota composition and gut hormone involved in carbohydrate metabolism ( GLP-1, FGF19,
      bile acids) with low protein diet supplemented with ketoanalogues.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Indoxyl Sulfate Plasmatic concentration</measure>
    <time_frame>After 3 months of diet</time_frame>
    <description>Concentration mesure of Indoxyl Sulfate Plasmatic</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TMAO uremic toxin concentraction ( TMAO, PCS) in plasma</measure>
    <time_frame>After 3 months</time_frame>
    <description>concentration mesure of uremic toxin in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TMAO uremic toxin concentraction in urine ( IS, PCS)</measure>
    <time_frame>After 3 months</time_frame>
    <description>concentration mesure of uremic toxin in urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composition of intestinal microbiota</measure>
    <time_frame>Before three months</time_frame>
    <description>sequencing 16s stool samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composition of intestinal microbiota</measure>
    <time_frame>After three months</time_frame>
    <description>sequencing 16s stool samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>After 3 months</time_frame>
    <description>oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin secretion</measure>
    <time_frame>After 3 months</time_frame>
    <description>oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secretion of gut hormone like GLP-1 and FGF19</measure>
    <time_frame>After 3 months</time_frame>
    <description>oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composition of bile acid</measure>
    <time_frame>After 3 months</time_frame>
    <description>composition of bile acid mesure by chromatography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of bile acid</measure>
    <time_frame>After 3 months</time_frame>
    <description>concentration of bile acid mesure by Chromatography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of endotoxinemia (LPS)</measure>
    <time_frame>After 3 months</time_frame>
    <description>LPS concentration mesure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional status</measure>
    <time_frame>After 3 months</time_frame>
    <description>Nutrional status will be determined with body weight, body composition with bioimpedecemetry, albumin, prealbumin, muscle status with hand grip.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calcemia</measure>
    <time_frame>After 3 months</time_frame>
    <description>calcemia mesure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observance of diet</measure>
    <time_frame>After 3 months</time_frame>
    <description>counting of returned ketosteril tablets</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Renal Failure</condition>
  <arm_group>
    <arm_group_label>referencial diet</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>0.8 g/kg/day of protein</description>
  </arm_group>
  <arm_group>
    <arm_group_label>protein very poor diet with additional keto-analogs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.4 g/kg/day of protein and 1 pill of Ketosteril/ 5kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>keto-analogs</intervention_name>
    <description>The patients that will be included in the experimental arm will have additional keto-analogs (1 pill/5 kg).</description>
    <arm_group_label>protein very poor diet with additional keto-analogs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CKD stage 4-5 with estimated glomerular filtration rate &lt; 30 ml/min/1,73m2

          -  No dialysis

          -  No history of kidney transplantation

          -  Non-diabetic (fasting glucose &lt;1.26 g / L, or no insulin or oral antidiabetic therapy)

          -  BMI between 18 and 30 kg / m2

          -  Patient followed in the nephrology department of Professor FOUQUE at the Lyon Sud
             hospital

          -  For women of childbearing age, at least one method of contraception recognized as
             effective

          -  Patient who gave consent to open participation and signed the consent to participate
             in the study

        Exclusion Criteria:

          -  Patient with progressive inflammatory, infectious, cardiovascular or neoplastic
             disease

          -  Patient refusing a dietary follow-up

          -  Patient having a planned transplant or dialysis project in the next 6 months.

          -  Patient having a colectomy, resection of the small intestine or cholecystectomy

          -  Patient who has received antibiotics, prebiotics, probiotics in the last 3 months.

          -  Patient treated with more than 2 g of calcium per day

          -  Patient using laxatives (more than 2 per day)

          -  Patient having:

          -  Uncontrolled metabolic acidosis (bicarbonatemia &lt;18 mM)

          -  Hyperparathyroidism (PTH greater than 5 times the upper limit of normal)

          -  Hypercalcemia (Calcium&gt; 2.55 mmol / L) or hypophosphoremia &lt;0.70 mmol / L

          -  Anemia (hemoglobinemia &lt;80g / L)

          -  Undernutrition criteria: albumin &lt;38 g / L or prealbumin &lt;0.3 g / L

          -  Known hypersensitivity to any of the substances or excipients of Ketosteril

          -  Subject in exclusion period of a previous study

          -  Patient not affiliated to social security

          -  Patient under guardianship or in the interests of justice

          -  Patient who is pregnant, breastfeeding or likely to become pregnant during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Laetitia KOPPE, MD</last_name>
    <phone>+33 4 72 67 87 15</phone>
    <phone_ext>+33</phone_ext>
    <email>Laetitia.koppe@chu-lyon.fr</email>
  </overall_contact>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>April 25, 2019</study_first_submitted>
  <study_first_submitted_qc>May 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2019</study_first_posted>
  <last_update_submitted>May 20, 2019</last_update_submitted>
  <last_update_submitted_qc>May 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

